Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.
URL: http://www.news-medical.net/news/20121115/EU-approves-Forxiga-for-treatment-of-type-2-diabetes.aspx
No comments:
Post a Comment